Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers

AMSTERDAM, November 30 - Elsevier, the world's leading publisher of scientific, medical
and technical products and services, today announced a major re-launch of
Embase, its comprehensive biomedical database which holds over 20 million
indexed records from more than 7,000 active, peer reviewed journals.

Embase has long played a key role in the advancement of new
biomedical and pharmaceutical insights. Now, new developments and updates
include:

    - Enabling all biomedical researchers to use Embase --
      extending its "usability" from information specialists to also include
      all biomedical and pharmaceutical scientists, and clinical and
      regulatory professionals.

    - New retrieval tools that further drive discovery, including
      quick and easy refining of search results and the display of indexed
      drug-drug and drug-disease relations.

    - Improved comprehensiveness through the addition of indexed
      articles-in-press and conference abstracts.

    - To signify the enhanced focus on biomedical answers, the
      product has a new, fresh look and feel to it.

Thomas Gutjahr, Head of the Knowledge Center at Actelion
Pharmaceuticals Ltd., comments: "I'm very impressed by all the new
improvements which I believe will greatly help with pin-pointing certain
searches, e.g. drug-drug interactions or drug-disease searches."

Embase supports researchers with key tasks such as tracking of
drug adverse events, comparing drug therapies, and Evidence Based Medicine
research. It provides researchers with deep insights and understanding from
the world's life sciences information, enabling effective discoveries towards
medical discovery and treatment.

ABOUT ELSEVIER

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com),
Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and
Nursing Consult (www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(www.scival.com) and MEDai's Pinpoint Review (www.medai.com),
which help research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contacts:

    Tom Reller
    Elsevier
    +1-215-239-3508
    t.reller@elsevier.com

    Emma Potter
    Kaizo PR
    +44-20-3043-4191
    Emma.potter@kaizo.net

Media Contacts: Tom Reller, Elsevier, +1-215-239-3508, t.reller at elsevier.com; Emma Potter, Kaizo PR, +44-20-3043-4191, Emma.potter at kaizo.net